Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PPBT
stocks logo

PPBT

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
0.000
-100%
--
--
-0.210
-86.78%
--
--
-0.260
-80.98%
Estimates Revision
The market is revising No Change the revenue expectations for Purple Biotech Ltd (PPBT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -10.92%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-10.92%
In Past 3 Month
1 Analyst Rating
up Image0
Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image0
Current: 2.530
sliders
Low
34.00
Averages
34.00
High
34.00
up Image0
Current: 2.530
sliders
Low
34.00
Averages
34.00
High
34.00
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$33
2024-11-15
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$33
2024-11-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$8 → $33
2024-09-20
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$8 → $33
2024-09-20
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$10 → $8
2024-08-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$10 → $8
2024-08-19
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Purple Biotech Ltd (PPBT.O) is -2.45, compared to its 5-year average forward P/E of -6.44. For a more detailed relative valuation and DCF analysis to assess Purple Biotech Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.44
Current PE
-2.45
Overvalued PE
15.18
Undervalued PE
-28.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.43
Current PS
0.00
Overvalued PS
6.31
Undervalued PS
-1.45

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

PPBT News & Events

Events Timeline

(ET)
2025-06-23
07:20:11
Purple Biotech presents preclinical data on CAPTN-3 antibody platform
select
2025-06-17 (ET)
2025-06-17
07:10:21
Purple Biotech announces initiation of Phase 2 study of NT219
select
2025-05-21 (ET)
2025-05-21
07:12:29
Purple Biotech reports Q1 EPS 17c
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-17Newsfilter
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

  • Phase 2 Study Initiation: Purple Biotech has launched a Phase 2 clinical study to evaluate NT219 in combination with pembrolizumab or cetuximab for treating recurrent and/or metastatic squamous cell carcinoma of the head and neck, aiming to overcome tumor resistance.

  • Mechanism and Collaboration: NT219 targets IRS1/2 and STAT3 pathways to induce tumor response, and the study is conducted in collaboration with the University of Colorado Anschutz Medical Campus, building on promising results from previous trials.

Preview
9.0
06-04Newsfilter
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

  • Company Announcement: Purple Biotech Ltd. will present its novel CAPTN-3 tri-specific antibody platform at the EACR 2025 Congress in Lisbon, focusing on immunotherapy advancements.

  • Research and Development: The company is advancing multiple therapies targeting tumor immune evasion and drug resistance, including CM24 and NT219, with promising results from clinical studies.

Preview
5.0
05-12NASDAQ.COM
Purple Biotech Appoints Shai Lankry As Chief Financial Officer

  • New Appointment: Purple Biotech Ltd. has appointed Shai Lankry as its Chief Financial Officer, bringing 20 years of experience and a background in strategic financial consulting.

  • Stock Performance: The company's shares are currently trading at $4 on the Tel Aviv Stock Exchange, reflecting a decrease of 2.44%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Purple Biotech Ltd (PPBT) stock price today?

The current price of PPBT is 2.53 USD — it has increased 0 % in the last trading day.

arrow icon

What is Purple Biotech Ltd (PPBT)'s business?

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

arrow icon

What is the price predicton of PPBT Stock?

Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Purple Biotech Ltd (PPBT)'s revenue for the last quarter?

Purple Biotech Ltd revenue for the last quarter amounts to -1.41M USD, decreased -68.52 % YoY.

arrow icon

What is Purple Biotech Ltd (PPBT)'s earnings per share (EPS) for the last quarter?

Purple Biotech Ltd. EPS for the last quarter amounts to -1952000.00 USD, decreased -60.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for Purple Biotech Ltd (PPBT)'s fundamentals?

The market is revising No Change the revenue expectations for Purple Biotech Ltd (PPBT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -10.92%.
arrow icon

How many employees does Purple Biotech Ltd (PPBT). have?

Purple Biotech Ltd (PPBT) has 9 emplpoyees as of July 18 2025.

arrow icon

What is Purple Biotech Ltd (PPBT) market cap?

Today PPBT has the market capitalization of 7.18M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free